Saudi Arabia Pharmaceutical Market

Saudi Arabia Pharmaceutical Market: Supportive Government Reforms and Rising Diseases Awareness to Fuel Revenue Growth from Branded Pharmaceuticals in Saudi Arabia: Industry Analysis and Opportunity Assessment, 2016-2026

Ask The Analyst Customization Available Request Methodology

Introduction

Saudi Arabia pharmaceutical market expected to maintain strong growth momentum owing to rapidly growing population coupled with strong influx of expatriates into the country. Saudi Arabia pharmaceutical market is dominated by branded drugs of various multinational companies, which are sold under second brand name in alliance with local companies and distributors. Saudi Arabia imports 80% of drugs from various countries, and the market in the country is dominated by several multinational companies. Increasing lifestyle diseases and strong brand loyalty for multinational drugs in Saudi Arabia are factors expected to drive demand for pharmaceuticals over the forecast period. Furthermore, increasing per capita income, growing healthcare infrastructure and increasing penetration of health insurance companies in the country is fuelling growth of the pharmaceuticals market in Saudi Arabia.

Market Value and Forecast

Saudi Arabia pharmaceutical market is estimated to be valued at US$ 5,209.5 Mn by 2016 end and is expected to expand at a CAGR of 9.0% over the forecast period (2016–2026).

Market Dynamics

Demand for pharmaceuticals is currently witnessing robust growth in Saudi Arabia, mainly due to increasing prevalence of non-communicable diseases and improved healthcare infrastructure. The pharmaceuticals market in Saudi Arabia is mainly dominated by MNCs, which account for largest share in the market. Rising health awareness and increased healthcare expenditure are factors expected to drive market growth in the near future. Macroeconomic factors such as increasing penetration of health insurance companies and healthcare reforms such as allowing 100% FDI in the pharmaceuticals sector is further projected to drive growth of the market. Other prominent growth drivers include rapidly growing number of religious tourists and increasing number of expatriates in the country. Saudi Arabia, being the largest market in GCC region, presents better investment opportunities for investors, and this is further augmented with mandatory insurance for expatriates in the country. However, lack of indigenous research capabilities and delays in patent registration are major factor expected to hamper overall growth of the Saudi Arabia pharmaceutical market over the forecast period.

Market Segmentation by Product

On the basis of product type, the market has been segmented into prescription products and over-the-counter (OTC) products. Prescription products segment is further sub-segmented into branded drugs and generic drugs. Branded drugs product type sub-segment is expected to exhibit highest growth over the forecast period as compared to other segments. Generic drugs sub-segment is expected to exhibit stable growth during the forecast period. This is mainly attributed to emergence of health insurance companies, which is a factor expected to result in lowering cost of treatment by encouraging healthcare providers to prescribe generic drugs.

saudi arabia pharmaceuticals market

Market Segmentation by Disease

On the basis of disease, the market has been segmented into cardiovascular diseases, diabetes, cancer, obesity, infectious diseases and other diseases. Cardiovascular disease segment is expected to exhibit highest growth among these segments over the forecast period, followed by the diabetes segment. Obesity segment is expected to exhibit significant growth owing to rising comorbidities such as cardiovascular diseases and diabetes.

Market Segmentation by Distribution Channel

On the basis of distribution channel, the market has been segmented into hospital pharmacies and retail pharmacies. Retail pharmacies segment accounts for highest revenue share in the Saudi Arabia pharmaceutical market currently, followed by the hospital pharmacies segment. Increasing modernized and westernised retail pharmacies and availability of wide variety of products is driving growth of retail pharmacies in the Saudi Arabia pharmaceutical market

Key Players

Some key players in the Saudi Arabia pharmaceutical market covered in this report are SPIMACO, Tabuk Pharmaceuticals Manufacturing Co., Juphar, Jamjoom Pharma, GlaxoSmithKline plc. Pfizer Inc., Novartis AG and Sanofi. The report also identifies company-specific strategies related to product development, market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.

Future Market Insights (FMI) offers a 10-year forecast of the Saudi Arabia pharmaceutical market between 2016 and 2026. In terms of value, the market is expected to register a CAGR of 9.0% over the forecast period. This study demonstrates market dynamics and trends that influence the current environment and future status of the pharmaceutical market in Saudi Arabia over the forecast period.

Report Description

The report examines Saudi Arabia pharmaceutical market for the period 2016–2026. The primary objective of the report is to offer insights on various products such as prescription products, branded drugs, generic drugs and over-the-counter (OTC) products.

The report begins by defining various economic and healthcare indicators in the country, followed by an overview of dynamics of the Saudi Arabia pharmaceutical market, which includes FMI analysis of key trends, drivers, restraints and opportunities and key players. It also includes insights into key regulations and reimbursement scenario. Impact analyses of key growth drivers and restraints based on the weighted average model have also been included in the report to better equip readers with meaningful insights on ongoing developments in the market.

Primary factors fuelling growth of the Saudi Arabia pharmaceutical market include increasing population and expatriates coupled with rapidly increasing healthcare infrastructure and proactive measures by the government to improve the healthcare systems in the country. Other factors driving demand for pharmaceuticals in Saudi Arabia are rising prevalence of lifestyle diseases and availability of better quality products from multinational companies.

On the contrary, factors such as lack of research and development capabilities and challenging regulatory environment in Saudi Arabia are factors expected to hamper market growth in the near future.

Based on product type, the market has been segmented into prescription products and OTC products. A detailed analysis has been provided for every segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

Based on disease type, the market has been segmented into cardiovascular diseases, diabetes, cancer, obesity, infectious diseases and other diseases. A detailed analysis has been provided for every segment in terms of market size, Y-o-Y growth rate, absolute $ opportunity and BPS analysis.

On the basis of distribution channel, retail pharmacies segment is expected to witness highest growth in Saudi Arabia pharmaceutical market over the forecast period. This trend is expected to be particularly prominent in Saudi Arabia, where doctors and patients hold higher preference for branded drugs over generic drugs. However, hospital pharmacies segment is expected to exhibit significant growth over the forecast period due to demand for generic drugs fuelled by increase in health insurance penetration.

The above sections — by product type, diseases and distribution channel— evaluate the present scenario and growth prospects of the Saudi Arabia pharmaceutical market for 2016–2026. We have considered 2015 as the base year and provided data for the forecast period.

In addition, it is imperative to note that in an ever-fluctuating developing economy, we not only conduct forecasts in terms of CAGR, but also provide analysis based on key parameters such as year-on-year (Y-o-Y) growth rates to understand the predictability of the market and to identify the right opportunities across the market.

The Saudi Arabia pharmaceutical market in terms of product, diseases and distribution channel are analyzed in terms of Basis Point Share (BPS) to understand individual segment’s relative contributions to market growth. This detailed level of information is important for identifying various key trends in the pharmaceutical market.

Another key feature of this report is the analysis of key segments in terms of absolute dollar opportunity. This is traditionally overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective of the pharmaceutical market.

In the final section of the report, competitive landscape of the coronary stents market is included to provide report audiences with a dashboard view, based on categories of providers in the value chain, their respective product portfolios and key developments. Key categories of providers covered in the report are drug manufacturers and distributors in the country. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the pharmaceutical market value chain and potential players for the same. Report audiences can gain segment-specific vendor insights to identify and evaluate key competitors based on in-depth assessment of capabilities and successes in the Saudi Arabia pharmaceutical market.

Detailed profiles of the providers are also included in the scope of the report to evaluate their long-term and short-term strategies, key offerings, SWOT analysis and recent developments in the KSA pharmaceuticals market. Key manufacturers included in the report are SPIMACO, Tabuk Pharmaceuticals Manufacturing Co., Julphar, Jamjoom Pharma, Glaxosmithkline plc. Pfizer Inc., Novartis AG and Sanofi.

Key Segments

  • Product Type
    • Prescription Products
      • Branded Drugs
      • Generic Drugs
    • Over The Counter (OTC) Products
  • Disease Type
    • Cardiovascular Diseases
    • Diabetes
    • Cancer
    • Obesity
    • Infectious Diseases
    • Other Diseases
  • Distribution Channel
    •  Hospital Pharmacies
    • Retail Pharmacies

Key Companies

  • SPIMACO
  • Tabuk Pharmaceuticals Manufacturing Co.
  • Julphar
  • Jamjoom Pharma
  • Glaxosmithkline plc.
  • Pfizer Inc.
  • Novartis AG
  • Sanofi

Saudi Arabia Pharmaceutical Market Reports - Table of Contents

1. Research Methodology

2. Assumptions & Acronyms

3. Executive Summary

4. Saudi Arabia Pharmaceutical Market Overview

4.1. Definition

4.2. GCC Pharmaceutical Market Overview 

4.3. Value Chain Analysis 

4.4. Trade Associations and Trade Fairs

4.5. PESTLE Analysis

4.6. Saudi Arabia Pharmaceuticals Market Overview, 2015–2026

5. Saudi Arabia Pharmaceutical Market-Healthcare Indicators

5.1. Macroeconomic Indicators

5.1.1. Saudi Arabia GDP (US$ Bn) and GDP Growth (%) 

5.1.2. GDP Growth (%) Comparison

5.1.3. Healthcare Expenditure (% of GDP), Saudi Arabia

5.1.4. Healthcare Expenditure (% of GDP) Comparison, 2014 

5.1.5. Healthcare Expenditure Per Capita (Current US$), 2014 

5.1.6. Saudi Arabia Healthcare Budget (US$ Mn) and Y-o-Y Growth (%) 

5.1.7. Health Expenditure, (% of GDP) Public Vs. Private Sector

5.1.8. FDI in Saudi Arabia

5.2. Demographic Indicators

5.2.1. Saudi Arabia Population (Mn) and Growth Rate (%)

5.2.2. Saudi Arabia Age Map, 2014

5.3. Healthcare Infrastructure Indicators

5.3.1. Number of Hospitals in Saudi Arabia

5.3.2. Number of Hospital Beds

5.3.3. Number of Healthcare Professionals in Saudi Arabia

5.3.4. Saudi Arabia and International Comparative Analysis / 1,000 Persons, 2013 (or Nearest Year) 

6. Market Dynamics

6.1. Macroeconomic Factors 

6.2. Demand Side Drivers 

6.3. Supply Side Drivers 

6.4. Market Opportunity 

6.5. Restraints 

6.6. Trends 

6.7. Saudi Arabia Drug Regulatory Impact Analysis

6.8. Intellectual Property Rights for Medicines in KSA

6.9. Pricing Scenario in KSA

6.10. Export-Import of Drugs in KSA

7. Saudi Arabia Pharmaceuticals Market, By Product Type

7.1. Market Forecast, By Product 

7.1.1. Prescription Products

7.1.1.1. Absolute $ Opportunity

7.1.1.2. Market Value Forecast

7.1.2. Branded Drugs

7.1.2.1. Absolute $ Opportunity

7.1.2.2. Market Value Forecast

7.1.3. Generic Drugs

7.1.3.1. Absolute $ Opportunity

7.1.3.2. Market Value Forecast

7.1.4. OTC Products

7.1.4.1. Absolute $ Opportunity

7.1.4.2. Market Value Forecast

7.2. Market Share & Basis Point (BPS) Analysis, By Product 

7.3. Y-o-Y Growth Comparison, By Product 

7.4. Market Attractiveness Analysis, By Product 

8. Saudi Arabia Pharmaceuticals Market, By Disease Type

8.1. Market Forecast, By Disease 

8.1.1. Cardiovascular Diseases

8.1.1.1 Absolute $ Opportunity

8.1.1.2. Market Value Forecast

8.1.2. Diabetes

8.1.2.1. Absolute $ Opportunity

8.1.2.2. Market Value Forecast

8.1.3. Cancer

8.1.3.1. Absolute $ Opportunity

8.1.3.2. Market Value Forecast

8.1.4. Obesity

8.1.4.1. Absolute $ Opportunity

8.1.4.2. Market Value Forecast

8.1.5. Infectious Diseases

8.1.5.1. Absolute $ Opportunity

8.1.5.2. Market Value Forecast

8.1.6. Other Diseases

8.1.6.1. Absolute $ Opportunity

8.1.6.2. Market Value Forecast

8.2. Market Share & Basis Point (BPS) Analysis, By Disease

8.3. Y-o-Y Growth Comparison, By Disease 

8.4. Market Attractiveness Analysis, By Disease 

9. Saudi Arabia Pharmaceuticals Market, By Distribution Channel

9.1. Market Forecast, By Distribution Channel

9.1.1. Hospital Pharmacies

9.1.1.1. Absolute $ Opportunity

9.1.1.2. Market Value Forecast

9.1.2. Retail Pharmacies

9.1.2.1. Absolute $ Opportunity

9.1.2.2. Market Value Forecast

9.2. Market Share & Basis Point (BPS) Analysis, By Distribution Channel

9.3. Y-o-Y Growth Comparison, By Distribution Channel

9.4. Market Attractiveness Analysis, By Distribution Channel

10. Competition Landscape

10.1. Competition Dashboard

10.2. Company Profiles (Details – Overview, SWOT Analysis, Strategy, Recent Developments)

10.3. Market Players

10.3.1. SPIMACO

10.3.2. Tabuk Pharmaceuticals Manufacturing Co. 

10.3.3. Julphar 

10.3.4. Jamjoom Pharma 

10.3.5. GlaxoSmithKline plc. 

10.3.6. Pfizer Inc. 

10.3.7. Novartis AG 

10.3.8. Sanofi 

Saudi Arabia Pharmaceutical Market Reports - List of Tables

Table 01: Saudi Arabia Pharmaceuticals Market Value Forecast, By Product Type, 2016–2026 (US$ Mn)

Table 02: Saudi Arabia Pharmaceuticals Market Value Forecast, By Product Type, 2016–2026 (US$ Mn)

Table 03: Saudi Arabia Pharmaceuticals Market Value Forecast, By Distribution Channel, 2016–2026 (US$ Mn)

Saudi Arabia Pharmaceutical Market Reports - List of Figures

Figure 01: GCC Pharmaceutical Market Snapshot (2015)

Figure 02: Saudi Arabia Pharmaceuticals Market Value (US$ Mn), 2015–2026

Figure: 03 Saudi Arabia GDP (US$ Bn) and GDP Growth (%) 

Figure: 04 GDP Growth (%) Comparison

Figure: 05 Healthcare Expenditure (% of GDP), Saudi Arabia

Figure: 06 Healthcare expenditure (% of GDP) Comparison, 2014 

Figure: 07 Healthcare Expenditure Per Capita (Current US$), 2014 

Figure: 08 Saudi Arabia Healthcare Budget (US$ Mn) and Y-o-Y Growth (%)  

Figure: 09 Health Expenditure, (% of GDP) Public Vs. Private Sector

Figure: 10 Saudi Arabia Population (Mn) and Growth Rate (%)

Figure: 11 Saudi Arabia Age Map, 2014

Figure: 12 Number of Hospitals in Saudi Arabia

Figure: 13 Number of Hospital Beds

Figure: 14 Number of Healthcare Professionals in Saudi Arabia

Figure: 15 Saudi Arabia and International Comparative Analysis / 1,000 Persons, 2013 (or Nearest Year) 

Figure 16: Saudi Arabia Pharmaceuticals Market (Mn) & Y-o-Y Growth (%) By Prescription Product Segment, 2015–2026

Figure 17: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Prescription Product Segment, 2015–2026 (US$ Mn)

Figure 18: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Branded Drugs Sub-segment, 2015–2026

Figure 19: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Branded Drugs Sub-segment, 2015–2026 (US$ Mn)

Figure 20: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Generic Drugs Sub-segment, 2015–2026

Figure 21: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by Generic Drugs Sub-segment, 2015–2026 (US$ Mn)

Figure 22: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by OTC Products Segment, 2015–2026

Figure 23: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by OTC Products Segment, 2014 – 2026 (US$ Mn)

Figure 24: Saudi Arabia Pharmaceuticals Market Share Analysis, by Product Type (%), 2016 & 2026

Figure 25: Saudi Arabia Pharmaceuticals Market Y-o-Y Growth (%), by Product Type, 2016–2026

Figure 26: Saudi Arabia Pharmaceuticals Market Attractiveness Index, by Product Type, 2016–2026

Figure 27: Saudi Arabia Pharmaceuticals Market (Mn) & Y-o-Y Growth (%) By Cardiovascular Diseases Segment, 2015–2026

Figure 28: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Cardiovascular Diseases Segment, 2015–2026 (US$ Mn)

Figure 29: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Diabetes Segment, 2015–2026

Figure 30: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Diabetes Segment, 2015–2026 (US$ Mn)

Figure 31: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Cancer Segment, 2015–2026

Figure 32: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by Cancer Segment, 2015–2026 (US$ Mn)

Figure 33: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Obesity Segment, 2015–2026

Figure 34: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by Obesity Segment, 2015–2026 (US$ Mn)

Figure 35: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Infectious Disease Segment, 2015–2026

Figure 36: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by Infectious Disease Segment, 2015–2026 (US$ Mn)

Figure 37: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Other Diseases Segment, 2015–2026

Figure 38: Saudi Arabia Pharmaceutical Absolute $ Opportunity, by Other Diseases Segment, 2015–2026 (US$ Mn)

Figure 39: Saudi Arabia Pharmaceuticals Market Share Analysis, by Disease Type (%), 2016 & 2026

Figure 40: Saudi Arabia Pharmaceuticals Market Y-o-Y Growth (%), by Disease Type, 2015–2026

Figure 42: Saudi Arabia Pharmaceuticals Market (Mn) & Y-o-Y Growth (%) By Hospital Pharmacies Segment, 2015–2026

Figure 43: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Hospital Pharmacies Segment, 2015–2026 (US$ Mn)

Figure 44: Saudi Arabia Pharmaceuticals Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies Segment, 2015–2026

Figure 45: Saudi Arabia Pharmaceuticals Market Absolute $ Opportunity, by Retail Pharmacies Segment, 2015–2026 (US$ Mn)

Figure 46: Saudi Arabia Pharmaceuticals Market Share Analysis, by Distribution Channel (%), 2016 & 2026

Figure 47: Saudi Arabia Pharmaceuticals Market Y-o-Y Growth (%), by Distribution Channel, 2016–2026

Figure 48: Saudi Arabia Pharmaceuticals Market Attractiveness Index, by Distribution Channel, 2016–2026